Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline Alfoscerate in Mild Cognitive Dysfunction
2025-520685-21-00Phase 4Authorised
- Sponsor
- University of Camerino
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of choline alfoscerate in Mild Cognitive Impairment (MCI), sponsored by University of Camerino. Primary endpoint: Slowing or stability of hippocampal and cortical atrophy and ventricular dilation. Planned start Jan 2025; status: authorised.
02
Drugs
choline alfoscerate
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2025-520685-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520685-21-00.